What side effects are associated with this type of intervention?

The most common treatments for Diabetic Macular Edema (DME) include anti-VEGF therapies such as ranibizumab. Known side effects of anti-VEGF treatments include eye pain, increased intraocular pressure, vitreous floaters, and potential risk of endophthalmitis. Combination therapies, like the one being studied with vamikibart and ranibizumab, may have additional side effects, but specific data on vamikibart is not yet available. Patients should discuss potential risks and benefits with their healthcare provider.

What prior FDA approvals exist?

The FDA has approved several anti-VEGF therapies for the treatment of Diabetic Macular Edema (DME). Ranibizumab (Lucentis) was one of the first anti-VEGF drugs approved for DME, demonstrating significant efficacy in reducing macular edema and improving vision. Aflibercept (Eylea) is another anti-VEGF agent approved for DME, offering similar benefits. Both drugs work by inhibiting vascular endothelial growth factor (VEGF), which plays a key role in the pathogenesis of DME. These treatments are similar to the ones being studied in the Vamikibart trial, which aims to enhance the effects of anti-VEGF therapy.

What other types of research exist?

Promising novel alternatives to Vamikibart for enhancing the effects of anti-VEGF therapy in Diabetic Macular Edema patients include Faricimab, a bispecific antibody targeting both VEGF and Angiopoietin-2, and KSI-301, an anti-VEGF antibody biopolymer conjugate designed for extended durability. Both have shown positive results in clinical trials and are expected to be significant options in 2024.

← Back to Search

Anti-VEGF inhibitor

Vamikibart + Ranibizumab for Diabetic Macular Edema

Phase 2

Waitlist Available

Research Sponsored by Hoffmann-La Roche

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of diabetes mellitus (Type 1 or Type 2)

Decreased visual acuity attributable primarily to DME

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, week 44 and week 48

Awards & highlights

Study Summary

This trial is testing a new drug, RO7200220, to see if it's more effective than ranibizumab alone in treating diabetic macular edema. The study will last 76 weeks.

Who is the study for?

This trial is for individuals with Type 1 or Type 2 diabetes who have decreased vision due to diabetic macular edema (DME) affecting the center of their retina. Women must use effective contraception and not be pregnant. Participants should not have other eye diseases, uncontrolled blood pressure, certain prior treatments like laser therapy or specific drugs, and no recent corticosteroid treatment in the study eye.Check my eligibility

What is being tested?

The study compares a new treatment combining Vamikibart with Ranibizumab against using only Ranibizumab for DME. It's randomized and double-masked, meaning neither participants nor researchers know who gets which treatment. The trial will last about 76 weeks and includes tests on how safe it is and how it affects the body.See study design

What are the potential side effects?

Potential side effects may include reactions at the injection site in the eye, increased risk of eye infection or inflammation, possible changes in intraocular pressure, as well as general side effects such as headache or nausea related to systemic absorption.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with diabetes (Type 1 or Type 2).

Select...

My vision loss is mainly due to diabetic macular edema.

Select...

I have swelling in the center of my retina due to diabetes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, week 44 and week 48

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, week 44 and week 48

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 44 and week 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants

Secondary outcome measures

Change from Baseline in CST at Week 24

Change from Baseline in CST at Week 36

Change from Baseline in Central Subfield Thickness (CST) at Week 48

+19 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm A: Vamikibart + RanibizumabExperimental Treatment2 Interventions

Participants will receive vamikibart, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.

Group II: Arm B: RanibizumabActive Control2 Interventions

Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ranibizumab

2017

Completed Phase 4

~2080

0 / 3Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Diabetic Macular Edema (DME) involve anti-VEGF therapies, such as ranibizumab, which inhibit the vascular endothelial growth factor (VEGF). VEGF promotes the growth of abnormal blood vessels in the retina, leading to fluid leakage and swelling in the macula. By blocking VEGF, these treatments reduce macular edema and improve vision. Vamikibart, currently being studied in combination with ranibizumab, may enhance the effects of anti-VEGF therapy, offering potentially greater reductions in macular edema and better visual outcomes. This is vital for DME patients as it directly targets the cause of vision impairment, aiming to preserve and improve their quality of life.